WAVE Life Sciences Q3 Earnings Call Highlights

Wave plans post-incretin maintenance trial in Q4 as cash runway extends into Q3 2028 (NASDAQ:WVE)

Wave Life Sciences Q3 2026: key WVE-007 and WVE-006 updates, FDA trial path, data catalysts, and cash runway.

Wave Life Sciences (WVE) Q3 2026 Earnings Call Transcript

RNA medicine company advances obesity and lung disease programs with $431M cash runway.

WAVE Life Sciences Q3 Earnings Call Highlights

WAVE Life Sciences (NASDAQ:WVE) reported higher third-quarter revenue and a wider net loss as it increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver disease. Revenue for the third quarter of 2026 totaled $13.2 million, up from $7.6 million a year ear

Wave Life Sciences Sets Oct. 27, 2026 Q3 Review, Expects WVE-006 Data in Q4 2026

Cash, cash equivalents and marketable securities totaled $490.6 million at June 30, with the balance expected to fund operations into the third quarter of 2028.